Elvisfan schreef op 15 mei 2019 om 22:35:
Hulskof, werkelijk een mooi aandeel hoor op LT
chat sessies aldaar ...
link : finance.yahoo.com/quote/CVRS?p=CVRS
CorPath GRX is the only FDA Cleared CE Marked Robotic system for Coronary and Peripheral Vascular Interventions. During Q1 - 2018, They increased their installed base to 37 systems by installing two new CorPath GRX systems and two upgrades, and sold 353 cassettes. Q2 - 2018, they also sold two new systems and two system upgrades, sold 390 cassettes, and increased their installed base to 41 systems. Q3 - 2018, they installed three new CorPath GRX systems and one system upgrade, sold 524 cassettes, and increased their installed base to 45 systems. Q4 - 2018, installed six new systems and one system upgrade, sold 522 cassettes, increasing their installed base to 52 systems. Q1 - 2019, recorded purchase orders for 11 CorPath GRX systems, and as of March 31, 2019, had installed nine of them, sold 602 cassettes, and increased their installed base of CorPath GRX systems to 61 systems. Their purchased orders increased 83% in Q1 2019 compared to Q4 2018 purchase orders, and 267% growth compared to purchase order received in Q1 2018. Based on their growth over the past year, and having received CE mark for a neurovascular indication, allowing them to sell neurovascular robots in 33 countries that accept CE mark, the sky's the limit. I believe they are well on their way to 100+ installed base systems, and 1000+ quarterly cassette sales.